glp-1 and kidneys Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations | Diabetes Therapy GLP-1 weight-loss drugs might help

Saxenda 3 mg daily for weight management): Proven efficacy with 5-8% weight reduction and cardiovascular outcome benefits in the LEADER trial Dulaglutide (Trulicity 0.75-4.5 mg weekly): Convenient once-weekly dosing with demonstrated cardiovascular benefit in the REWIND trial Tirzepatide (Mounjaro for diabetes

Tel: +1-604-822-2156, Fax: +1-604-822-2316, [email protected] Copyright 2013 Korean Endocrine Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited

Microdosing GLP-1s: The bottom line While microdoses of GLP-1s havent been clinically tested, microdosing has the potential to help people who struggle with access, cost, or side effects

These technologies potentially allow the setup of an in vitro test system, which resembles the in vivo situation as closely as possible 27